Anvatabart opadotin by Ambrx Biopharma for Gastric Cancer: Likelihood of Approval

Anvatabart opadotin is under clinical development by Ambrx Biopharma and currently in Phase I for Gastric Cancer.

Payments to Medicare Plan Brokers Need Reform, MedPAC Says

Payments to brokers who enroll people in Medicare plans should be reformed so that no preferential treatment is given for enrollment in Medicare Advantage (MA)

October 12, 2024

FDA approves Vertex and CRISPR’s Casgevy as first CRISPR-edited therapy for beta-thalassemia

The FDA has approved Vertex Pharmaceuticals and CRISPR Therapeutics’ Casgevy to treat beta-thalassemia, Vertex said Tuesday, making it the first-ever CRISPR-edited therapy for the rare

January 17, 2024

Bernie Sanders Has COVID; Global Fake Ozempic Problem; Nitazenes, the New Fentanyl?

Some links may require registration or subscription. Please note that in observance of the upcoming holiday, Morning Break will not publish on New Year’s Day

December 30, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.